Rhythm Pharmaceuticals (RYTM) Reports In-Line Q3 EPS

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q3 EPS of ($0.76), in-line with the analyst estimate of ($0.76). Revenue for the quarter came in at $22.5 million versus the consensus estimate of $22.17 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• B.Riley Assumes Anika Therapeutics (ANIK) at Buy
• Anthropic delays planned IPO from October to November - WSJ